TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT03571568: A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL

Sponsor: BioInvent International AB · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 140 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,023,790

Rescue Site Savings

+$2,002,770

Unlock Full NCT03571568 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03571568 Rescue Dossier →